Development and Therapeutic Potential of Calpain Inhibitors

Advances in Pharmacology

Volumn 37, Issue C, 1996, Pages 117-152

  Wang, Kevin K W ^a   Yuen, Po wai ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011232693     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60949-7     Document Type: Article

References (203)

1. Alvarez M.E., Houck D.R., White C.B., Brownell J.E., Bobko M.A., Rodger C.A., Stawicki M.B., Sun H.H., Gillum A.M., and Cooper R. Isolation and structure elucidation of two new calpain inhibitors from Streptomyces griseus. J. Antibiot. 47 (1994) 1195-1201
2. Anagli J., Hagmann J., and Shaw E. Investigation of the role of calpain as a stimulus- response mediator in human platelets using new synthetic inhibitors. Biochem. J. 274 (1991) 497-502
3. Angliker H., Wikstrom P., Rauber P., and Shaw E. The synthesis of lysylfluoromethanes and their properties as inhibitors of trypsin, plasmin and cathepsin B. Biochem. J. 241 (1987) 871-875
4. 2+-activated neutral protease (μCANP) deduced from its cDNA sequence. FEBS Lett. 205 (1986) 313-317
5. Aoyagi T., and Umezawa H. In: Reich E., Rifkin D.B., and Shaw E. (Eds). "Proteases and Biological Control" (1975), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 429-454
6. Arai A., Kessler M., Lee K., and Lynch G. Calpain inhibitors improve the recovery of synaptic transmission from hypoxia in hippocampal slices. Brain Res. 532 (1990) 63-68
7. Arai A., Vanderklish P., Kseeler M., Lee K., and Lynch G. A brief period of hypoxia causes proteolysis of cytoskeletal proteins in hippocampal slices. Brain Res. 555 (1991) 276-280
8. Ariyoshi H., Shiba E., Kambayashi J., Sakon M., Tsujinaka T., Uemura Y., and Mori T. Characteristics of various synthetic peptide calpain inhibitors and their application for the analysis of platelet reaction. Biochem Int. 23 (1991) 1019-1033
9. Ariyoshi H., Shiba E., Sakon M., Kambayashi J., Kawasaki T., Kang J., Kawashima S., and Mori T. Membrane binding and autolytic activation of calpain-I in human platelets. Biochem. Int. 27 (1992) 335-341
10. Arlinghaus L., Mehdi S., and Lee K.S. Improved posthypoxic recovery with a membrane-permeable calpain inhibitor. Eur. J. Pharmacol. 209 (1991) 123-125
11. Arrigoni E., and Cohadon F. Calcium-activated neutral protease activities in brain trauma. Neurochem. Res. 16 (1991) 483-487
12. Ashall F., and Goate A.M. Role of the β-amyloid precursor protein in Alzheimer's disease. Trends Biochem. Sci. 19 (1994) 42-46
13. Atsma D.E., Bastiassnse E.M.L., Jerzewski A., Van der Valk L.J.M., and Van der Laarse A. Role of calcium-activated neutral protease (calpain) in cell death in cultured neonatal rat cardiomyocytes during metabolic inhibition. Circ. Res. 76 (1995) 1071-1078
14. Azuma M., David L.L., and Shearer T.R. Cysteine protease inhibitor E64 reduces the rate of formation of selenite cataract in the whole animal. Curr. Eye Res. 10 (1991) 657-666
15. Azuma M., David L.L., and Shearer T.R. Superior prevention of calcium ionophore cataract by E64d. Biochim. Biophys. Acta 1180 (1992) 215-220
16. Azuma M., Inoue E., Oka T., and Shearer T.R. Proteolysis by calpain is an underlying mechanism for formation of sugar cataract in rat lens. Curr. Eye Res. 14 (1995) 27-34
17. Badalamentle M.A., Hurst L.C., and Stracher A. Neuromuscular recovery using calcium protease inhibition after median nerve repair in primates. Proc. Natl. Acad. Sci. USA 86 (1989) 5983-5987
18. Badalamentle M.A., Hurst L.C., and Stracher A. Recovery after delayed nerve repair: Influence of a pharmacologic adjunct in a primate model. J. Reconstr. Microsurg. 8 (1992) 319-397
19. Baldassare J.J., Bakshian S., Knipp M.A., and Fisher G.J. Inhibition of fibrinogen receptor expression and serotonin release by leupeptin and antipain. J. Biol. Chem. 260 (1985) 10531-10535
20. 2-induced myelopathy in rat spinal cord. CNS Trauma 1 (1984) 131-137
21. 2+-activated neutral proteinase associated with purified myelin of rat CNS. J. Neurochem. 45 (1985) 581-588
22. Banik N.L., Hogan E.L., Powers J.M., and Smith K.P. Proteolytic enzymes in experimental spinal cord injury. J. Neurol. Sci. 73 (1986) 245-256
23. Banik N.L., Chakrabarti A.K., Konat G.W., Gantt W.G., and Hogan E.L. Calcium-activated neutral proteinase (calpain) activity in C6 cell line: Compartmentation of mu and m calpain. J. Neurosci. Res. 31 (1992) 708-714
24. Barrett A.J., Kembhawi A.A., Brown M.A., Kirschke H., Knight C.G., Tamai M., and Hananda K. L-trans-EpoxysuccinyI-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201 (1982) 189-198
25. Bartus, R. T., Eveleth, D. D., Jr., Lynch, G. S., and Powers, J. C. (1992). Use of calpain inhibitors in the inhibition and treatment of neurodegeneration. PCT Int. Appl., WO 9211850 Al.
26. Bartus R.T., Baker K.L., Heiser A.D., Sawyer S.D., Dean R.L., Elliott P.J., and Straub J.A. Postischemic Administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J. Cereb. Blood Flow Metab. 14 (1994) 537-544
27. Bartus R.T., Hayward N.J., Elliott P.J., Sawyer S.D., Baker K.L., Dean R.L., Akiyama A., Straub J.A., Harbeson S.L., Li Z., and Powers J. Calpain inhibitor AK295 protects neurons from focal brain ischemia: Effects of postocclusion intra-arterial administration. Stroke 25 (1994) 2265-2270
28. Bi X., Tocco G., and Baudry M. Calpain-mediated regulation of AMPA receptors in adult rat brain. Neuroreport 6 (1994) 61-64
29. Brass L.F., and Shattil S.J. Inhibition of thrombin-induced platelet activation by leupeptin. Implications for the participation of calpain in the initiation of platelet activation. J. Biol. Chem. 263 (1988) 5210-5216
30. 2+ entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar Purkinje cells. J. Neurosci. 14 (1994) 187-197
31. Brorson J.R., Marceccilli C.L., and Miller R.J. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke 26 (1995) 1259-1267
32. Caner H., Collins J.L., Harris S.M., Kassell N.F., and Lee K.S. Attenuation of AMPA-induced neurotoxicity by a calpain inhibitor. Brain Res. 607 (1993) 354-356
33. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 (1988) 623-634
34. Choi D.W., Maulucci-Gedde M., and Kriegstein A.R. Glutamate neurotoxicity in cortical culture. J. Neurosci. 7 (1987) 357-368
35. 2-macroglobulin. Biochem. J. 248 (1987) 589-594
36. Crawford C., Mason R.W., Wikstrom P., and Shaw E. The design of peptidyldiazo-methane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B. Biochem. J. 253 (1988) 751-758
37. Croall D.E., Morrow J.S., and DeMartino G.N. Limited proteolysis of the erythrocyte membrane skeleton by calcium-dependent proteinases. Biochim. Biophys. Acta 882 (1986) 287-296
38. Croall D.E., and Demartino G.N. Calcium-activated neutral protease (calpain) system: Structure, function, and regulation. Physiol. Rev. 71 (1991) 813-847
39. David L.L., and Shearer T.R. Beta-crystallins insolubilized by calpain II in vitro contain cleavage sites similar to beta-crystallins insolubilized during cataract. FEBS Lett. 324 (1993) 265-270
40. David L.L., Shearer T.R., and Sahih M. Sequence analaysis of lens beta crystallins suggests involvement of calpain in cataract formation. J. Biol. Chem. 268 (1993) 1937-1940
41. Di Stasi A.M., Gallo V., Ceccarini M., and Petrucci T.C. Neuronal fodrin proteolysis occurs independently of excitatory amino acid-induced neurotoxicity. Neuron 6 (1991) 445-454
42. Dingledine R., McBain C.J., and McNamara J.O. Excitatory amino acid receptors in epilepsy. Trends Pharmacol. Sci. 11 (1990) 334-338
43. Dixon C.E., Clifton G.L., Lighthall J.W., Yaghmai A., and Hayes R.L. A controlled cortical impact model of traumatic brain injury in the rat. J. Neurosci. Methods 39 (1991) 253-262
44. Dolle R.E., Singh J., Whipple D., Osifo I.K., Speier G., Graybill T.L., Gregory J.S., Harris A.L., Helaszek C.T., Miller R.E., and Ator M.A. Aspartyl α-((diphenylphosphinyl)oxy)methyl ketones as novel inhibitors of interleukin-1β converting enzyme. Utility of the diphenylphosphinic acid leaving group for the inhibition of cysteine proteases. J. Med. Chem. 38 (1995) 220-222
45. Edelstein C.L., Wieder E.D., Yaqoob M.M., Gengaro P.E., Burke T.J., Nemenoff R., and Schrier R.W. Calpain is a mediator of hypoxia-induced rat renal proximal tubular injury. J. Invest, Med. 43 (1995) 351A
46. Edelstein C.L., Wieder E.D., Yaqoob M.M., Gengaro P.E., Burke T.J., Nemenoff R.A., and Schrier R.W. The role of cysteine proteases in hypoxia-induced rat renal proximal tubular injury. Proc. Natl. Acad. Sci. USA 92 (1995) 7662-7666
47. Findlay J.M., Macdonald R.L., and Weir B.K. Current concepts of pathophysiology and management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cerebrovasc. Brain Metab. Rev. 3 (1991) 336-361
48. Fineman I., Hovda D., Smith M., Yoshino A., and Becker D. Concussive brain injury is associated with a prolonged accumulation of calcium: A Wa autoradiographic study. Brain Res. 624 (1993) 94-102
49. Foley P.L., Kassell N.F., Hudson S.B., and Lee K.S. Hemoglobin penetration in the wall of the rabbit basilar artery after subarachnoid hemorrhage and intracisternal hemoglobin injection. Acta Neurochir. Wien 123 (1993) 82-86
50. Fox J.E., Reynolds C.C., and Phillips D.R. Calcium-dependent proteolysis occurs during platelet aggregation. J. Biol. Chem. 258 (1983) 9973-9981
51. Franco Jr. A., and Lansman J.B. Calcium entry through stretch inactivated ion channels in mdx myotubes. Nature 344 (1990) 670-673
52. Fukui I., Tanaka K., and Murachi T. Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. Biochem. Biophys. Res. Commun. 162 (1989) 559-566
53. Giordano C., Calabretta R., Gallina C., Consalvi V., Scandurra R., Chiaia Noya F., and Franchini C. Synthesis and inhibiting activities of 1-peptidyl-2-haloacetyl hydrazines toward cathepsin B and calpains. Eur. J. Med. Chem. 28 (1993) 297-311
54. Goldberg M.P., and Choi Q.W. Combined oxygen and glucose deprivation in cortical cell culture: Calcium-dependent and calcium-independent mechanism of neuronal injury. J. Neurosci. 13 (1993) 3510-3524
55. Graybill T.L., Dolle R.E., Osifo I.K., Schmidt S.J., Gregory J.S., Harris A.L., and Miller M.S. Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides. Bioorg. Med. Chem. Lett. 5 (1995) 387-392
56. Green G.D.J., and Shaw E. Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases. J. Biol. Chem. 256 (1981) 1923-1928
57. Greenwood A.F., and Jope R.S. Brain G-protein proteolysis by calpain: Enhancement by lithium. Brain Res. 636 (1994) 320-326
58. Gupta R.P., and Abou-Donia M.B. Diisopropyl phosphorofluoridate (DFP) treatment alters calcium-activated proteinase activity and cytoskeletal proteins of the hen sciatic nerve. Brain Res. 677 (1995) 162-166
59. Guroff G. A neutral calcium-activated proteinase from the soluble fraction of rat brain. J. Biol. Chem. 239 (1964) 149-155
60. Hajimohammadreza I., Probert A.W., Coughenour L.L., Borosky S.A., Boxer P.A., Marcoux F.W., and Wang K.K.W. Inhibition of calmodulin-dependent protein kinase-II attenuates excitotoxic amino acid mediated neuronal death. J. Neurosci. 15 (1995) 4093-4101
61. Hanada K., Tamai M., Morimoto S., Yamagishi M., Ohmura S., Sawada J., and Tanaka I. Studies on thiol protease inhibitors. Part I. Isolation and characterisation of E64, a new thiol protease inhibitor. Agric. Biol. Chem. 42 (1978) 523-528
62. Harbeson S.L., Abelleira S.M., Akiyama A., Barrett III R., Carroll R.M., Straub J.A., Tkacz J.N., Wu C., and Musso G.F. Stereospecific synthesis of peptidyl α-keto amides as inhibitors of calpain. J. Med. Chem. 37 (1994) 2918-2929
63. Harris A.L., Gregory J.S., Maycock A.L., Graybill T.L., Osifo I.K., Schmidt S.J., and Dolle R.E. Characterization of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (acy1oxy)methyl ketones as inhibitors of the enzyme. Bioorg. Med. Chem. Lett. 5 (1995) 393-398
64. Hayes R.L., Jenkins L.W., and Lyeth B.G. Neurotransmitter-mediated mechanisms of traumatic brain injury. J. Neurotrauma 9 (1992) S173-S187
65. Hirai S., Kawasaki H., Yaniv M., and Suzuki K. Degradation of transcription factors, c-Jun and c-Fos, by calpain. FEBs Lett. 287 (1991) 57-61
66. Hiramatsu K.-I., Kassell N.F., and Lee K.S. Improved posthypoxic recovery of synaptic transmission in gerbil neocortical slices treated with a calpain inhibitor. Stroke 24 (1993) 1725-1728
67. Hong S.C., Goto Y., Lanzino G., Soleau S., Kassell N.F., and Lee K.S. Neuroprotec-tion with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 25 (1994) 663-669
68. Hori H., Yasutake A., Minematsu Y., and Powers J.C. Inhibition of human leukocyte elastase, pancreatic elastase and cathepsin G by peptide ketones. In: Deber C.M., Hruby V.J., and Kopple K.D. (Eds). "Peptides: Structure and Function. Proceedings of the Ninth American Peptide Symposium (1985), Pierce Chem. Co., Rockford, IL. 819-822
69. Huang Z., McGowan E.B., and Detwiler T.C. Ester and amide derivatives of E64c as inhibitors of platelet calpains. J. Med. Chem. 35 (1992) 2048-2054
70. 2+. II. Identification of the kinase activating factor as a proteolytic enzyme. Biochemistry 7 (1968) 2116-2121
71. Iizuka H., Iwasaki Y., Yamamoto T., and Kadoya S. Morphometric assessment of drug effects in experimental spinal cord injury. J. Neurosurg. 65 (1986) 92-98
72. Iizuka K., Kawaguchi H., and Yasuda H. Calpain is activated during hypoxic myocardial cell injury. Biochem. Med. Metab. Biol. 46 (1991) 427-431
73. Iizuka K., Kawaguchi H., and Kitabatake A. Effects of thiol protease inhibitors on fodrin degradation during hypoxia in cultured myocytes. J. Mol. Cell Cardiol. 25 (1993) 1101-1109
74. Imajoh S., Kawasaki H., and Suzuki K. The amino-terminal hydrophobic region of the small subunit of calcium-activated neutral protease (CANP) is essential for its activation by phosphatidylinositol. J. Biochem. 99 (1986) 1281-1284
75. Imperiali B. Synthetic fluoropeptides as a pharmacologically useful compound. "Synthetic Peptides in Biotechnology," (1988), Alan R. Liss, New York 97-129
76. Imperiali B., and Abeles R.H. Inhibition of serine proteases by peptidyl fluoromethyl ketones. Biochemistry 25 (1986) 3760-3767
77. Inaba T., Hirayama Y., and Fujinaga N. Inhibition of cathepsin B1 by E-64, a thiol proteinase inhibitor, and its derivatives. Agric. Biol. Chem. 43 (1979) 655-656
78. Ishii H., Kuboki M., Fujii J., Hiraishi S., and Kazama M. Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. Thromb. Res. 57 (1990) 847-861
79. Ishima R., Tamura A., Akasaka K., Hamaguchi K., Makino K., Murachi T., Hatanaka M., and Maki M. Structure of the active 27-residue fragment of human calpastatin. FEBS Lett. 294 (1991) 64-66
80. Ishiura S., Nonaka I., and Sugita H. Calcium-activated neutral protease: Its degradarive role in muscle cells. In: Ebashi S. (Ed). "Muscular Dystrophy" (1980), University of Tokyo Press, Tokyo 265-282
81. Iwamoto N., Thangnipon W., Crawford C., and Emson P.C. Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. Brain Res. 561 (1991) 177-180
82. 2+/calmodulin-dependent protein kinase II. J. eurosci. Res. 34 (1993) 642-647
83. Johnson P., and Hammer J.L. Calpain and calpastatin levels in dystrophic hamster skeletal muscles. Int. J. Biochem. 20 (1988) 1227-1230
84. 2+, and its effect on the neurofilament triplet. J. Neurosci. Res. 13 (1985) 391-403
85. Kassell N.F., Sasaki T., Colohan A.R.T., and Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 16 (1985) 562-572
86. Krantz A., Copp L.J., Coles P.J., Smith R.A., and Heard S.B. Peptidyl (acyloxy)- methyl ketones and the quiescent affinity label the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry 30 (1991) 4678-4687
87. Kuboki M., Ishii H., Horie S., and Kazama M. Procalpain I in cytoplasm is translocated onto plasma and granule membranes during platelet stimulation with thrombin and then activated on the membranes. Biochem. Biophys. Res. Commun. 185 (1992) 1122-1127
88. Kumamoto T., Ueyama H., Watanabe S., Yoshioka K., Miike T., Goll D.E., Ando M., and Tsuda T. Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. Acta Neuropathol. 89 (1995) 399-403
89. Lampi K.J., Kadoya K., Azuma M., David L.L., and Shearer T.R. Comparison of cell-permeable calpain inhibitors and E64 in reduction of cataract in cultured rat lenses. Toxical. Appl. Pharmacol. 117 (1992) 53-57
90. Leary R., Larsen D., Watanabe H., and Shaw E. Diazomethyl ketone substrate derivatives as active-site directed inhibitors of thiol proteinases: Papain. Biochemistry 16 (1977) 5857-5861
91. Lee K., Frank S., Vanderklish P., Arai A., and Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. USA 88 (1991) 7233-7237
92. Li H., and Buchan A.M. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. 13 (1993) 933-939
93. Li Z., Patil G.S., Golubski Z.E., Hori H., Tehrani K., Foreman J.E., Eveleth D.D., Bartus R.T., and Powers J.C. Peptide α-keto ester, α-keto amide, and α-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem. 36 (1993) 3472-3480
94. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330 (1994) 613-622
95. Maki M., Takano E., Mori H., Sato A., Murachi T., and Hatanaka M. All four internally repetitive domains of pig calpastatin possess inhibitory activities against calpains I and II. FEBS Lett. 233 (1987) 174-180
96. Maki M., Bagci H., Hamaguchi K., Ueda M., Murachi T., and Hatanaka M. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J. Biol. Chem. 264 (1989) 18866-18869
97. Manev H., Favaron M., Siman R., Guidotti A., and Costa E. Glutamate neurotoxicity is independent of calpain I inhibition in primary cultures of cerebellar granule cells. J. Neurochem. 57 (1991) 1288-1295
98. Marcantonio J.M., and Duncan G. Calcium-induced degradation of the lens cytoskeleton. Biochem. Soc. Trans. 19 (1991) 1148-1150
99. March K.L., Wilensky R.L., Roeske R.W., and Hathaway D.R. Effects of thiol protease inhibitors on cell cycle and proliferation of vascular smooth muscle cells in culture. Circ. Res. 72 (1993) 413-423
100. Mata M., Kupina N., and Fink D.J. Calpain II in rat peripheral nerve. Brain Res. 564 (1991) 328-331
101. Matsueda R., Umeyama H., Puri R.N., Bradford H.N., and Colman R.W. Potent affinity labeling peptide inhibitors of calpain. Chem. Lett. (1990) 191-194
102. Matsumura Y., Kusuoka H., Inoue M., Hori M., and Kamada T. Protective effect of the protease inhibitor leupeptin against myocardial stunning. J. Cardiovasc. Pharmacol. 22 (1993) 135-142
103. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16 (1993) 109-114
104. McBride W., Lange R.A., and Hillis L.D. Restenosis after successful coronary angioplasty. N. Engl. J. Med. 318 (1988) 1734-1737
105. McConkey D.J., Hartzell P., Nicotera P., and Orrenius S. Calcium activated DNA fragmentation kills immature thymocytes. FASEB J. 3 (1989) 1843-1849
106. 2+ increase in the target. FASEB J. 4 (1990) 2661-2664
107. McGowan E.B., Becker E., and Denviler T.C. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem. Biophys. Res. Commun. 158 (1989) 432-435
108. Mehdi S., Angelastro M.R., Wiseman J.S., and Bey P. Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. Biochem. Biophys. Res. Commun. 157 (1988) 1117-1123
109. Meldrum B., and Garthwaite J. Excitatory amino acid neurotoxicity and neurodegener-ative disease. Trends Pharmacol. Sci. 11 (1990) 379-387
110. Minami N., Tani E., Maeda Y., Tamaura I., and Fukami M. Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. J. Neurosurg. 76 (1992) 111-118
111. Molinari M., Maki M., and Carafoli E. Purification of μ-calpain by a novel affinity chromatography approach. New insights into the mechanism of the interaction of the protease with targets. J. Biol. Chem. 270 (1995) 14576-14581
112. Murachi T. Intracellular regulatory system involving calpain and calpastatin. Biochem. Int. 18 (1989) 263-294
113. Nixon R.A., Saito K.I., Gryspan F., Griffin W.P., Katayama S., Honda T., Mohan P.S., Shea T.B., and Beermann M. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. NY Acad. Sci. 747 (1994) 77-91
114. Ogura K., Maeda M., Nagai M., Tanaka T., Nomoto K., and Murachi T. Purification and structure of a novel cysteine proteinase inhibitor, strepin P-1. Agric. Biol. Chem. 49 (1985) 799-805
115. O'Halloran T., Beckerle M.C., and Burridge K. Identification of talin as a major cytoplasmic protein implicated in platelet activation. Nature 317 (1985) 449-451
116. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254 (1991) 1515-1518
117. Omura, S., Tanaka, H., Shimoi, K., and Liu, J. R. (1993). Pyrrole propionic acid amide (cystamidine A) manufacture with Streptomyces, and its use as calpain inhibitor. Eur. Pat. Appl. EP 569122 A1.
118. Onji T., Takagi M., and Shibata N. Calpain abolishes the effect of filamin on the actomyosin system in platelets. Biochim. Biophys. Acta 912 (1987) 283-286
119. Parkes C., Kembhavi A.A., and Barrett A.J. Calpain inhibition by peptide epoxides. Biochem. J. 230 (1985) 509-516
120. Peet N.P., Burkhart J.P., Angelastro M.R., Giroux E.L., Mehdi S., Bey P., Kolb M., Neises B., and Schirlin D. Synthesis of peptidyl fluoromethyl ketones and peptidyl α-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, and rat and human neutrophil cathepsin G. J. Med. Chem. 33 (1990) 394-399
121. Persson H., and Karlsson J.-O. Calpain activity in a subcellular fraction enriched in partially degraded CNS myelin fragments compared with myelin. Neurosci. Lett. 130 (1991) 81-84
122. Pliura D.H., Bonaventura B.J., Smith R.A., Coles P.J., and Krantz A. Comparative behavior of calpain and cathepsin B toward peptidyl acyloxymethyl ketones, sulfonium methyl ketones and other potential inhibitors of cysteine proteinases. Biochem. J. 288 (1992) 759-762
123. Postmantur R., Hayes R.L., Dixon E., and Taft W.C. Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. J. Neurotrauma 11 (1994) 533-545
124. Posner A., Raser K.J., Hajimohammadreza I., Yuen P.-W., and Wang K.K.W. Aurintricarboxylic acid is an inhibitor of calpain I and II. Biochem. Mol. Biol. Int. 36 (1995) 291-299
125. Puri R.N., Zhou F.X., Bradford H., Hu C.J., Colman R.F., and Colman R.W. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch. Biochem. Biophys. 271 (1989) 346-358
126. Puri R.N., Hu C.J., Matsueda R., Umeyama H., and Colman R.W. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide. Thromb. Res. 65 (1992) 533-547
127. Puri R.N., Matsueda R., Umeyama H., Bradford H.N., and Colman R.W. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3)nitro-2-pyridinesulfenyl)-cysteine. Eur. J. Biochem. 214 (1993) 233-241
128. 2-A selective inhibitor of thrombin-induced platelet aggregation. Thromb. Res. 72 (1993) 183-191
129. Rami A., and Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 609 (1993) 67-70
130. Rasnick D. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal. Biochem. 149 (1985) 461-465
131. Richard I., Broux R.O., Allamand V., Fougerousse F., Chiannikulchai N., Bourg N., Brenguier L., Devaud C., Pasturaud P., Roudaut C., et al. Mutation in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81 (1995) 27-40
132. Saido T.C., Suzuki H., Yamazaki H., Tanoue K., and Suzuki K. In situ capture of mu-calpain activation in platelets. J. Biol. Chem. 268 (1993) 7422-7426
133. Saido T.C., Sorimachi H., and Suzuki K. Calpain: New perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 8 (1994) 814-822
134. Saito K.-L., Elce J.S., Hamos J.E., and Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90 (1993) 2628-2632
135. Saito M., Kawaguchi N., Hashimoto M., Kodama T., Higuchi N., Tanaka T., Nomoto K., and Murachi T. Purification and structure of novel cysteine proteinase inhibitors, staccopins P1 and P2, from Staphylococcus tanabeensis. Agric. Biol. Chem. 51 (1987) 861-868
136. Sakai K., Akanuma H., Imahori K., and Kawashima S. A unique specificity of a calcium activated neutral protease indicated in histone hydrolysis. J. Biochem. 101 (1987) 911-918
137. ++ activated neutral protease in platelets. Thromb. Res. 24 (1981) 207-214
138. Salvesen G., Parkes C., Abrahamson M., Grubb A., and Barrett A.J. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. 234 (1986) 429-434
139. Sarin A., Adams D.H., and Henkart P.A. Protease inhibitors selectively block T cell receptor-triggered programmed cell death in murine T cell hybridoma and activated peripheral T cells. J. Exp. Med. 178 (1993) 1693-1700
140. Sarin A., Clerici M., Blatt S.P., Hendrix C.W., Shearer G.M., and Henkart P.A. Inhibition of activation-induced programmed cell death and restoration of defective immune response of HIV+ donors by cysteine protease inhibitors. J. Immunol. 153 (1994) 862-872
141. 2+-activated neutral protease from muscle. Biochem. Biophys. Res. Commun. 110 (1983) 256-261
142. Sasaki T., Kikuchi T., Yumoto N., Yoshimura N., and Murachi T. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J. Biol. Chem. 259 (1984) 12489-12494
143. Sasaki T., Kikuchi T., Fukui I., and Murachi T. Inactivation of calpain I and calpain II by specificity-oriented tripeptidyl chloromethyl ketones. J. Biochem. 99 (1986) 173-179
144. Sasaki T., Kishi M., Saito M., Tanaka T., Higuchi N., Kominami E., Katunuma N., and Murachi T. Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J. Enz. Inhib. 3 (1990) 195-201
145. Schlaepfer W.W., and Micko S. Calcium-dependent alternations of neurofilament proteins of rat peripheral nerve. J. Neurochem. 32 (1979) 244-249
146. Schlaepfer W.W., Lee C., Lee V.M., and Zimmerman U.J. An immunoblot study of neurofilament degradation in situ and during calcium-activated proteolysis. J. Neurochem. 44 (1985) 502-509
147. Schmaier A.H., Bradford H., Silver L.D., Farber A., Scott C.F., Schutsky D., and Coiman R.W. High molecular weight kininogen is an inhibitor of platelet calpain. J. Clin. Invest. 77 (1986) 1565-1573
148. Schroder E., Phillips C., Garman E., Harlos K., and Crawford C. X-ray crystallographic structure of a papain-leupeptin complex. FEBS Lett. 315 (1993) 38-42
149. Seubert P., Lee K., and Lynch G. Ischemia triggers NMDA receptor linked cytoskeletal proteolysis in hippocampus. Brain Res. 492 (1989) 366-370
150. Shaw E. Cysteinyl proteinases and their selective inactivation. Adv. Enzymol. 63 (1990) 271-347
151. Shearer T.R., David L.L., and Anderson R.S. Selenite cataract. Curr. Eye Res. 6 (1987) 289-300
152. Shearer T.R., Azuma M., David L.L., and Murachi T. Amelioration of cataracts and proteolysis in cultured lenses by cysteine protease inhibitor E64. Opthalmol. Vis. Sci. 32 (1991) 533-540
153. Siman R., and Noszek J.C. Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron 1 (1988) 279-287
154. Siman R., Card J.P., and Davis L.G. Proteolytic processing of beta amyloid precursor by calpain I. J. Neurosci. 10 (1990) 2400-2411
155. Sorimachi H., Imajoh O.S., Emori Y., Kawasaki H., Ohno S., Minami Y., and Suzuki K. Molecular cloning of a novel mammalian calcium dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J. Biol. Chem. 264 (1989) 20106-20111
156. 2+) binding domain. J. Biol. Chem. 268 (1993) 19476-19482
157. Spencer M.J., Croall D.E., and Tidbal J.G. Calpains are activated in necrotic fiber from mdx dystrophic mice. J. Biol. Chem. 270 (1995) 10909-10914
158. Squier M.K.T., Miller A.C.K., Malkinson A.M., and Cohen J.J. Calpain activation in apoptosis. J. Cell. Physiol. 159 (1994) 229-237
159. Stein R.L., Strimpler A.M., Edwards P.D., Lewis J.J., Mauger R.C., Schwartz J.A., Stein M.M., Trainor D.A., Wildonger R.A., and Zottola M.A. Mechanism of slow-binding inhibition of human leukocyte elastase by trifluoromethyl ketones. Biochemistry 26 (1987) 2682-2689
160. Stone S.R., Rennex D., Wikstrom P., Shaw E., and Hofsteenge J. Peptidyldiazomethanes. A novel mechanism of interaction with prolyl endopeptidase. Biochem. J. 283 (1992) 871-876
161. Suda H., Aoyagi T., Hamada M., Takeuchi T., and Umezawa H. Antipain, a new protease inhibitor isolated from actinomycetes. J. Antibiot. 25 (1972) 263-266
162. Sugita H., Ishiura S., Suzuki K., and Imahori K. Inhibition of epoxide derivatives on chicken calcium-activated neutral protease (CANP) in vitro and in vivo. J. Biochem. 87 (1980) 339-341
163. Suzuki K. Reaction of calcium-activated neutral protease (CANP) with an epoxysuccinyl derivative (E64c) and iodoacetic acid. J. Biochem. 93 (1983) 1305-1312
164. Suzuki K. Calcium activated neutral protease: Domain structure and activity regulation. Trends Biochem. Sci. 12 (1987) 103-105
165. 2+ ions. J. Biochem. 90 (1981) 275-278
166. Suzuki K., Tsuji S., and Ishirua S. Effect of calcium ion on the inhibition of calcium-activated neutral protease by leupeptin, antipain and epoxysuccinate derivatives. FEBS Lett. 136 (1981) 119-122
167. Suzuki K., Shimizu K., Hamamoto T., Nakagawa Y., Hamakubo T., and Yamamuro T. Biochemical demonstration of calpains and calpastatin in osteoarthritic synovial fluid. Arthritis Rheum. 33 (1990) 728-732
168. Suzuki K., Shimizu K., Hamamoto T., Nakagawa Y., Murachi T., and Yamamuro T. Characterization of proteoglycan degradation by calpain. Biochem. J. 285 (1992) 857-862
169. Szomor Z., Shimizu K., Fujimori Y., Yamamoto S., and Yamauro T. Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. Ann. Rheum. Dis. 54 (1995) 477-483
170. Taft W.C., Yang K., Dixon C.E., and Hayes R.L. Microtubule-associated protein 2 level in hippocampus following traumatic brain injury. J. Neurotrauma 9 (1992) 281-290
171. Takano E., Kitahara A., Sasaki T., Kannagi R., and Murachi T. Two different molecular species of pig calpastatin. Structural and functional relationship between 107 kDa and 68 kDa molecules. Biochem. J. 235 (1986) 97-102
172. Takano E., Ma H., Yang H.Q., Maki M., and Hatanaka M. Preference of calcium-dependent interactions between calmodulin-like domains of calpain and calpastatin subdo-mains. FEBS Lett. 362 (1995) 93-97
173. Takano H., Kawaguchi H., Iizuka K., and Yasuda H. Platelet aggregation induced by platelet-activating factor is suppressed by cystine protease inhibitor. Biochem. Med. Metab. Biol. 45 (1991) 41-47
174. Tallant E.A., Brumley L.M., and Wallace R.W. Activation of a calmodulin-dependent phosphatase by a Ca2+-dependent protease. Biochemistry 27 (1988) 2205-2211
175. Tamai M., Yokoo C., Murata M., Oguma K., Sota K., Sato E., and Kanaoka Y. An efficient synthetic method for ethyl (+)-(2S,3S)-3-[(S)-3-methyl-1-(3-methylbutyloar-bamoyl]-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteinases. Chem. Pharm. Bull. 35 (1987) 1098-1104
176. Toda G., Matsushita S., Kuramoto K., Oda S., Ezaki H., Hattori A., and Kawashima S. Calcium-activated neutral protease inhibitor (E64c) and reperfusion for experimental myocardial infarction. Jpn. Heart J. 30 (1989) 375-386
177. Tolnai S., and Korecky B. Calcium-dependent proteolysis and its inhibition in the ischemic rat myocardium. Can. J. Cardiol. 2 (1986) 42-47
178. Towatari T., Tanaka K., Yoshikawa D., and Kataunuma M. Purification and properties of a new cathepsin from rat liver. J. Biochem. 84 (1978) 659-672
179. Toyo-Oka T., Shimizu T., and Masaki T. Inhibition of proteolytic activity of calcium activated neutral protease by leupeptin and antipain. Biochem. Biophys. Res. Commun. 82 (1978) 484-491
180. Tsujinaka T., Kajiwara Y., Kambayashi J., Sakon M., Higuchi N., Tanaka T., and Mori T. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem. Biophys. Res. Commun. 153 (1988) 1201-1208
181. Turner P.R., Westwood T., Regen C.M., and Steinhardt R.A. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 335 (1988) 735-738
182. Turner P.R., Schultz R., Ganguly B., and Steinhardt R.A. Proteolysis results in altered leak channel kinetics and elevated free calcium in mdx muscle. J. Membr. Biol. 133 (1993) 243-251
183. Valentino K., Newcomb R., Gadbois T., Singh T., Bowersox S., Bitner S., Justice B.A., Tamashiro D., Hoffman B.B., Ciaranello R., Milianich G., and Ramachandran J. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA 90 (1993) 7894-7897
184. van der Westhuyzen D., Matsumoto K., and Etlinger J.D. Easily releasable myofilaments from skeletal and cardiac muscles maintained in vitro. J. Biol. Chem. 256 (1981) 11791-11797
185. Van Heyningen R. Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 184 (1959) 194-195
186. Wagner B.M., Smith R.A., Coles P.J., Copp L.J., Ernest M.J., and Krantz A. In vivo inhibition of cathepsin B by peptidyl (acy1oxy)methyl ketones. J. Med. Chem. 37 (1994) 1833-1840
187. Wang K.K.W. Developing selective inhibitors of calpain. Trends Pharmacol. Sci. 11 (1990) 139-142
188. Wang K.K.W., Villalobo A., and Roufogalis B.D. Calmodulin binding proteins as calpain substrates. Biochem. J. 262 (1989) 693-706
189. Wang K.K.W., and Yuen P.-W. Calpain inhibition: An overview of its therapeutic potential. Trends Pharmacol. Sci. 15 (1994) 412-419
190. Wang K.K.W., Nath R., Posner A., Raser K.J., Buroker-Kilgore M., Ye Q., Takano E., Hatanaka M., Maki M., Marcoux F.W., Caner H., Collins J.L., Fergus A., Lee K.S., Lunney E.A., Hays S.J., and Yuen P.-w. Alpha-mercaptoacrylic acid derivatives are selective non-peptide and calcium-binding domain-targeting calpain inhibitors. Proc. Natl. Acad. Sci. (1996) In press
191. Watt F., and Molloy P.L. Specific cleavage of transcription factors by the thiol protease, m-calpain. Nucleic Acids Res. 21 (1993) 5092-5100
192. Waxman S.G. Demyelination in spinal cord injury and multiple sclerosis: What can we do to enhance functional recovery. J. Neurotrauma 9 Suppl 1 (1993) S105-S117
193. Wilcox D., and Mason R.W. Inhibition of cysteine proteinases in lysosomes and whole cells. Biochem. J. 285 (1992) 495-502
194. Wilensky R.L., March K.L., and Hathaway D.R. Restenosis in an atherosclerotic rabbit model is reduced by a thiol protease inhibitor. J. Am. Coll. Cardiol. 17 (1991) 268A
195. Yamamoto S., Shimizu K., Shimizu K., Suzuki K., Nakagawa Y., and Yamamuro T. Calcium-dependent cysteine proteinase (calpain) in human arthritic synovial joints. Arthritis Rheum. 35 (1992) 1309-1317
196. Yang H.Q., Ma H., Takano E., Hatanaka M., and Maki M. Analysis of calcium-dependent interaction between amino-terminal conserved region of calpastatin functional domain and calmodulin-like domain of μ-calpain large subunit. J. Biol. Chem. 269 (1994) 18977-18984
197. Yano Y., Shiba E., Kambayashi J., Sakon M., Kawasaki T., Fujitani K., Kang J., and Mori T. The effects of calpeptin (a calpain specific inhibitor) on agonist-induced microparticle formation from the platelet plasma membrane. Thromb. Res. 71 (1993) 385-396
198. 2+-dependent cysteine proteinase, isolated from the same tissue. Biochim. Biophys. Acta 798 (1984) 252-259
199. Yoshida H., Murachi T., and Tsukare I. Distribution of calpain I, calpain II, and calpastatin in bovine lens. Invest. Ophthalmol. Vis. Sci. 26 (1985) 953-956
200. Yoshida H., Murachi T., and Tsukahara I. Age-related changes of calpain II and alpha-crystallin in the lens of hereditary cataract (Nakano) mouse. Curr. Eye Res. 4 (1985) 983-988
201. Yoshida K.-L., Sorimachi Y., Fujiwara M., and Hironaka K. Calpain is implicated in rat myocardial injury after ischemia or reperfusion. Jpn. Circ. J. 59 (1995) 40-48
202. Zimmerman U.-J.P., and Schlaepfer W.W. Calcium-activated neutral protease (CANP) in brain and other tissues. Prog. Neurobiol. 23 (1984) 63-78
203. Zumbrunn A., Stone S., and Shaw E. Synthesis and properties of Cbz-Phe Arg-CHN2 (benzyloxycarbonylphenylalanylarginyldiazornethane) as a proteinase inhibitor. Biochem. J. 250 (1988) 621-623